{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":38,"n_cols":5,"rows_kept":38,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[11,2,11,3],[12,2,12,3],[15,2,15,3],[17,2,17,3],[17,4,17,5],[18,2,18,3],[18,4,18,5],[19,2,19,3],[19,4,19,5],[20,2,20,3],[21,2,21,3],[25,2,25,3],[26,2,26,3],[27,2,27,3],[28,2,28,3],[30,2,30,3],[31,2,31,3],[35,2,35,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910466679703321"]
[null,null,"Autore",null,"Beaumarchais Pierre-Augustin Caron de"]
[null,null,"Titolo",null,"Almaviva et Rosine : Pantomime en trois actes, melee de danses / / Pierre-Augustin Caron de Beaumarchais"]
[null,null,"Pubbl/distr/stampa",null,"[Place of publication not identified] : , : Ligaran, , 2015"]
[null,null,"ISBN",null,"2-335-05574-7"]
[null,null,"Descrizione fisica",null,"1 online resource (47 p.)"]
[null,null,"Disciplina",null,"842.009"]
[null,null,"Soggetti",null,"French drama - History and criticism"]
[{"$nulls":4},"French drama"]
[{"$nulls":4},"French literature"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Francese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,"Nota di contenuto",null,"Couverture; Page de Copyright; Page de titre; Personnages; Acte premier; Scène première; Scène II; Scène III; Scène IV; Scène V; Scène VI; Scène VII; Scène VIII; Scène IX; Acte II; Scène première; Scène II; Scène III; Scène IV; Scène V; Scène VI; Scène VII; Scène VIII; Scène IX; Scène X; Scène XI; Scène XII; Scène XIII; Scène XIV; Acte III; Scène première; Scène II; Scène III; Scène IV; Scène V; Scène VI; Scène VII; Scène VIII"]
[null,null,null,"Sommario/riassunto","Extrait : \"\"SCÈNE PREMIÈRE : Les Paysans sont occupés à orner la maison de Bartholo, et à élever un trône de fleurs pour la fête de Rosine, que le docteur veut célébrer. Sept heures sonnent : les paysans pressent leur ouvrage. SCÈNE II : Figaro entre, il gronde les paysans. Tout devrait être prêt ; Rosine est peut-être éveillée. Figaro et les paysans se disputent.\"\"À PROPOS DES ÉDITIONS LIGARANLes éditions LIGARAN proposent des versions numériques de qualité de grands livres de la littérature classique mais également des livres rares en partenariat avec la BNF. Beaucoup de soins sont apportés"]
[null,"2.","Record Nr.",null,"UNINA9910954395803321"]
[null,null,"Autore",null,"Patlak Margie"]
[null,null,"Titolo",null,"Developing biomarker-based tools for cancer screening, diagnosis, and treatment : the state of the science, evaluation, implementation, and economics / / Margie Patlak and Sharyl Nass, rapporteurs ; National Cancer Policy Forum"]
[null,null,"Pubbl/distr/stampa",null,"Washington, DC, : National Academies Press, c2006"]
[null,null,"ISBN",null,"0-309-18061-9"]
[{"$nulls":4},"1-280-70492-6"]
[{"$nulls":4},"9786610704927"]
[{"$nulls":4},"0-309-65814-4"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (112 p.)"]
[null,null,"Disciplina",null,"616.99/4075"]
[null,null,"Soggetti",null,"Tumor markers"]
[{"$nulls":4},"Biochemical markers"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Bibliographic Level Mode of Issuance: Monograph"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"Frontmatter -- Reviewers -- Contents -- Introduction -- Overview of Technologies Used to Discover Cancer Biomarkers -- Meeting the Technical Challenges of Biomarker Validation and Qualification -- Coordinating the Development of Biomarkers and Targeted Therapies -- Biomarker Development and Regulatory Oversight -- Assessment and Adoption of Biomarker-Based Technologies -- Economic Impact of Biomarkers -- Clinical Development Strategies for Biomarker Utilization Discussion -- Strategies for Implementing Standardized Biorepositories Discussion -- Strategies for Determining Analytic Validity and Clinical Utility of Biomarkers Discussion -- Strategies to Develop Biomarkers for Early Detection Discussion -- Mechanisms for Developing an Evidence Base Discussion -- Evaluation of Evidence in Decision Making Discussion -- Incorporating Biomarker Evidence Into Clinical Practice Discussion -- Acronyms -- Glossary -- References -- Appendixes -- Appendix A Workshop Agenda -- Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants."]
[null,null,null,"Sommario/riassunto","Research has long sought to identify biomarkers that could detect cancer at an early stage, or predict the optimal cancer therapy for specific patients. Fueling interest in this research are recent technological advances in genomics, proteomics, and metabolomics "]
[{"$nulls":4},"that can enable researchers to capture the molecular fingerprints of specific cancers and fine-tune their classification according to the molecular defects they harbor. The discovery and development of new markers of cancer could potentially improve cancer screening, diagnosis, and treatment. Given the potential impact cancer biomarkers could have on the cost effectiveness of cancer detection and treatment, they could profoundly alter the economic burden of cancer as well. Despite the promise of cancer biomarkers, few biomarker-based cancer tests have entered the market, and the translation of research findings on cancer biomarkers into clinically useful tests seems to be lagging. This is perhaps not surprising given the technical, financial, regulatory, and social challenges linked to the discovery, development, validation, and incorporation of biomarker tests into clinical practice.  To explore those challenges and ways to overcome them, the National Cancer Policy Forum held the conference \"Developing Biomarker-Based Tools for Cancer Screening, Diagnosis and Treatment: The State of the Science, Evaluation, Implementation, and Economics\" in Washington, D.C., from March 20 to 22, 2006.  At this conference, experts gave presentations in one of six sessions. In addition, seven small group discussions explored the policy implications surrounding biomarker development and adoption into clinical practice. Developing Biomarker-based Tools for Developing Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics-Workshop Summary presents the conference proceedings and will be used by an Institute of Medicine (IOM) committee to develop consensus-based recommendations for moving the field of cancer biomarkers forward."]